drugset / Trial / NCT04339868

Terlipressin for Refractory Septic Shock

NCT04339868

Phase 2 Unknown 130 enrolled Mahidol University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Norepinephrine was recommended as the first vasopressor for septic shock resuscitation. For the patient who did not response to high dose norepinephrine, epinephrine was recommended. Vasopressin was also recommended as an alternative vasopressor, in case patient did not response to norepinephrine and or epinephrine. Terlipressin, a selective V1 receptor binding with long half life, was reported that it main action is to increase blood pressure via the different mechanism from norepinephrine and epinephrine. To use terlipressin, combine with norepinephrine and or epinephrine among refractory septic shock, could decrease the usage dose of norepinephrine and epinephrine as well as lower the side effects of too high adrenergic stimuli.

Timeline

Start
2020-04-03
Primary completion
2025-03-31
Completion
2025-07-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Terlipressin Peptide 100 ug
Comparator Epinephrine Other / unclassified
Comparator Norepinephrine Other / unclassified